Efficacy and Safety of Oteseconazole in Recurrent Vulvovaginal Candidiasis
Abstract
BACKGROUND: Management of recurrent vulvovaginal candidiasis (RVVC) is an unmet clinical challenge without approved treatment in the United States. Oteseconazole is a novel oral selective inhibitor of fungal CYP51, designed to treat RVVC without off-target toxicities. VIOLET comprised two global, phase 3, multicenter, randomized, double-blind, placebo-controlled trials (CL-011 and CL-012). The primary objective was to evaluate oteseconazole efficacy through week 48. Key secondary objectives evaluated time to first recurrence, safety, and patient-reported outcomes. METHODS: Women with three or more symptomatic acute vulvovaginal candidiasis (VVC) episodes within the previous 12-month period, including the screening episode (in which the VVC episode cleared with fluconazole induction therapy), were randomly assigned 2:1 at baseline (maintenance phase) to 150 mg of oral oteseconazole daily for 7days and then once weekly for 11 weeks or to matching placebo for 12 weeks. Time-to-first-recurrence data were collected during the maintenance phase. Posttreatment follow-up was 36 weeks. RESULTS: Among 656 women (326 in CL-011 and 330 in CL-012), the averaged percentage of participants with one or more RVVC episodes through week 48 was 6.7% (range, 6.5 to 7.4%) in CL-011 and 3.9% (3.7 to 4.6%) in CL-012 in the oteseconazole groups versus 42.8% (41.3 to 45.0%) and 39.4% (38.0 to 42.6%) in the corresponding placebo groups (P<0.001). Among oteseconazole-treated participants in CL-011 and CL-012 who experienced an RVVC episode (n=22), the mean time to recurrence was 45.7 and 47.2 weeks versus 27.8 and 33.1 weeks for placebo-treated participants (n=84), respectively (hazard ratio [95% confidence interval], 0.11 [0.06 to 0.21] for CL-011 and 0.08 [0.04 to 0.17] for CL-012; P<0.001). Types and frequencies of treatment-emergent adverse events (TEAEs) were similar between groups in both trials, with no drug-related serious TEAEs or adverse effects on pregnancy outcomes, liver function, or QT interval. CONCLUSIONS: Oral oteseconazole was effective in preventing acute VVC recurrence and treating RVVC through week 48 in the CL-011 and CL-012 trials, with mostly mild TEAEs. (Funded by Mycovia Pharmaceuticals, Inc., ClinicalTrials.gov numbers, NCT03562156 for CL-011 and NCT03561701 for CL-012.)
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In Phase 3 clinical trials, oteseconazole was shown to be highly efficacious in preventing recurrence of acute VVC episodes in women with RVVC, even women with azole-resistant C. albicans or C. glabrata infections.
“In Phase 3 clinical trials (CL-011 (NCT03562156) and CL-012 (NCT03561701), oteseconazole was shown to be highly efficacious in preventing recurrence of acute VVC episodes in women with RVVC, even women with azole-resistant C. albicans or C. glabrata infections. 31”
From Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis (2022) · cites this paper as [31]
Cites
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200 · see citing works
Self-citationGlobal burden of recurrent vulvovaginal candidiasis: a systematic review
Denning, D. W., Kneale, M., Sobel, J. D., & Rautemaa-Richardson, R. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30103-8 · Cited by 639 · see citing works
Self-citationRecurrent vulvovaginal candidiasis
Sobel, J. D. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.06.067 · Cited by 502 · see citing works
Self-citationMaintenance Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis
Sobel, J. D., Wiesenfeld, H. C., Martens, M., Danna, P., Hooton, T. M., Rompalo, A., Sperling, M., Livengood, C., Horowitz, B., Von Thron, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033114 · Cited by 487 · see citing works
Self-citationEstimation of Direct Healthcare Costs of Fungal Diseases in the United States
Benedict, K., Jackson, B. R., Chiller, T., & Beer, K. D. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy776 · Cited by 438 · see citing works
Vulvovaginal Candidiasis: A Current Understanding and Burning Questions
Willems, H. M. E., Ahmed, S. S., Liu, J., Xu, Z., & Peters, B. M. (2020) · Journal of Fungi · doi:10.3390/jof6010027 · Cited by 357 · see citing works
Sherrard, J., Wilson, J., Donders, G., Mendling, W., & Jensen, J. S. (2018) · International Journal of STD & AIDS · doi:10.1177/0956462418785451 · Cited by 297 · see citing works
Self-citationFoxman, B., Muraglia, R., Dietz, J.-P., Sobel, J. D., & Wagner, J. (2013) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0b013e318273e8cf · Cited by 261 · see citing works
Self-citationDesign and optimization of highly-selective fungal CYP51 inhibitors
Hoekstra, W. J., Garvey, E. P., Moore, W. R., Rafferty, S. W., Yates, C. M., & Schotzinger, R. J. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.05.068 · Cited by 195 · see citing works
Fluconazole-Resistant Candida albicans Vulvovaginitis
Marchaim, D., Lemanek, L., Bheemreddy, S., Kaye, K. S., & Sobel, J. D. (2012) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31827307b2 · Cited by 195 · see citing works
Self-citationRecurrent vulvovaginal candidiasis
Blostein, F., Levin-Sparenberg, E., Wagner, J., & Foxman, B. (2017) · Annals of Epidemiology · doi:10.1016/j.annepidem.2017.08.010 · Cited by 180 · see citing works
Warrilow, A. G. S., Hull, C. M., Parker, J. E., Garvey, E. P., Hoekstra, W. J., Moore, W. R., Schotzinger, R. J., Kelly, D. E., & Kelly, S. L. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03707-14 · Cited by 173 · see citing works
Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species
Sobel, J. D., & Sobel, R. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1476490 · Cited by 168 · see citing works
Self-citationDonders, G., Bellen, G., Byttebier, G., Verguts, L., Hinoul, P., Walckiers, R., Stalpaert, M., Vereecken, A., & Van Eldere, J. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.06.029 · Cited by 127 · see citing works
Self-citationNyirjesy, P., Peyton, C., Weitz, M. V., Mathew, L., & Culhane, J. F. (2006) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000239103.67452.1a · Cited by 96 · see citing works
Donders, G. G. G., Babula, O., Bellen, G., Linhares, I. M., & Witkin, S. S. (2008) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2008.01830.x · Cited by 88 · see citing works
Self-citationGarvey, E. P., HOEKSTRA, W., Schotzinger, R. J., Sobel, J. D., Lilly, E. A., & Fidel, P. L. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00185-15 · Cited by 83 · see citing works
Self-citationBrand, S. R., Degenhardt, T. P., Person, K., Sobel, J. D., Nyirjesy, P., Schotzinger, R. J., & Tavakkol, A. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.03.001 · Cited by 78 · see citing works
Self-citationSchell, W. A., Jones, A. M., Garvey, E. P., Hoekstra, W. J., Schotzinger, R. J., & Alexander, B. D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01817-16 · Cited by 74 · see citing works
A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis
Brand, S. R., Sobel, J. D., Nyirjesy, P., Ghannoum, M. A., Schotzinger, R. J., & Degenhardt, T. P. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1204 · Cited by 61 · see citing works
Shahid, Z., & Sobel, J. D. (2009) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.03.021 · Cited by 55 · see citing works
Self-citationCollins, L. M., Moore, R., & Sobel, J. D. (2020) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0000000000000496 · Cited by 55 · see citing works
Self-citationda Rosa, M. I., Silva, B. R., Pires, P. S., Silva, F. R., Silva, N. C., Silva, F. R., Souza, S. L., Madeira, K., Panatto, A. P. R., & Medeiros, L. R. (2012) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2012.12.001 · Cited by 51 · see citing works
Ignjatović, A., Arsić-Arsenijević, V. S., Golubović, M., Đenić, S., Momčilović, S., Trajković, A., Ranđelović, M., Ćirić, V. M., & Otašević, S. (2020) · Journal of Fungi · doi:10.3390/jof6030113 · Cited by 25 · see citing works
Donders, G. G. G., Grincevičienė, Š., Bellen, G., Jaeger, M., ten Oever, J., & Netea, M. G. (2018) · American Journal of Reproductive Immunology · doi:10.1111/aji.12811 · Cited by 21 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Hoenigl, M., Arastehfar, A. A., Arendrup, M. C., Brüggemann, R. J. M., Carvalho, A., Chiller, T. M., Chen, W., Egger, M., Feys, S., Gangneux, J., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00074-23 · Cited by 160 · see citing works
Antifungals: From Pharmacokinetics to Clinical Practice
do Carmo, A., Rocha, M. J., Pereirinha, P., Tomé, R., & Costa, E. (2023) · Antibiotics · doi:10.3390/antibiotics12050884 · Cited by 112 · see citing works
“The study concluded that oteseconazole was effective in preventing acute vulvovaginal candidiasis recurrence and treating recurrent vulvovaginal candidiasis in the CL-011 and CL-012 trials, with reduced adverse effects [73,154,155].”
BackgroundMartens, M. G., Maximos, B., Degenhardt, T., Person, K., Curelop, S., Ghannoum, M., Flynt, A., & Brand, S. R. (2022) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2022.07.023 · Cited by 86 · see citing works
Self-citationDonders, G., Sziller, I. O., Paavonen, J., Hay, P., de Seta, F., Bohbot, J. M., Kotarski, J., Vives, J. A., Szabo, B., Cepuliené, R., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.934353 · Cited by 82 · see citing works
Self-citationFungal biofilms in human health and disease
Ramage, G., Kean, R., Rautemaa-Richardson, R., Williams, C., & Lopez-Ribot, J. L. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01147-0 · Cited by 72 · see citing works
“This is also the case for the first-in-class oral triterpenoid, ibrexafungerp, for use in RVVC 154,159–162 .”
InfluentialClinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis
Neal, C. M., & Martens, M. G. (2022) · SAGE Open Medicine · doi:10.1177/20503121221115201 · Cited by 56 · see citing works
Host-microbe interaction paradigms in acute and recurrent vulvovaginal candidiasis
MacAlpine, J., & Lionakis, M. S. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.08.018 · Cited by 36 · see citing works
Wang, X., Chen, L., Ruan, H., Xiong, Z., Wang, W., Qiu, J., Song, W., Zhang, C., Xue, F., Qin, T., et al. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00778-23 · Cited by 31 · see citing works
Fluconazole-Resistant Vulvovaginal Candidosis: An Update on Current Management
Akinosoglou, K., Livieratos, A., Asimos, K., Donders, F., & Donders, G. G. G. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121555 · Cited by 30 · see citing works
“In phase III studies by Martens et al. and Sobel/Donders et al., otesecona-zole showed very promising results [38,54], leading to a recurrence rate as low as 4 to 5% in cases of FRVVC.”
Self-citationMolecular association of Candida albicans and vulvovaginal candidiasis: focusing on a solution
David, H., & Solomon, A. P. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1245808 · Cited by 29 · see citing works
New Antifungals for Vulvovaginal Candidiasis: What Is Their Role?
Sobel, J. D. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad002 · Cited by 23 · see citing works
Self-citationInsights and advances in recurrent vulvovaginal candidiasis
Galán, J. S. J., Poliquin, V., & Gerstein, A. C. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011684 · Cited by 24 · see citing works
A Comprehensive Overview of Candida albicans as the Leading Pathogen in Vulvovaginal Candidiasis
Srb, N., Talapko, J., Meštrović, T., Fureš, R., Stupnišek, M., Srb, A. M., & Škrlec, I. (2025) · Journal of Fungi · doi:10.3390/jof11090632 · Cited by 26 · see citing works
“The recently approved oteseconazole is effective in both acute and recurrent VVC [120].”
State-of-the-Art Review: Managing Vulvovaginal Candidiasis
Rautemaa‐Richardson, R., Sobel, J. D., Stone, N. R. H., Seta, F. D., Cassone, A., Vieira‐Baptista, P., Comar, M., Warris, A., & Roselletti, E. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf673 · Cited by 24 · see citing works
“Oteseconazole administered in a weekly dosing regimen for a 12-week period after antifungal induction therapy showed to be effective in preventing VVC recurrence in women with RVVC compared to placebo [91–93].”
Self-citationLiu, Z., Yang, H., Huang, R., Li, X., Sun, T., & Zhu, L. (2025) · Clinical Microbiology Reviews · doi:10.1128/cmr.00284-24 · Cited by 16 · see citing works
Vandecruys, P., Baldewijns, S., Sillen, M., Genechten, W. V., & Dijck, P. V. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2233696 · Cited by 15 · see citing works
“This study comprised two trials, conducted between August 2018 and October 2020, with a multicenter, randomized, double-blind, placebo-controlled design (CL-011, NCT03562156 and CL-012, NCT03561701), to evaluate the efficacy and safety of oral oteseconazole for the treatment of RVVC [71].”
BackgroundMethodOteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis: A Drug Review
Lanier, C., & Melton, T. C. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231195649 · Cited by 14 · see citing works
“22,23 A gold standard trial would be to compare the approved treatment regimen for fluconazole versus otesec-onazole.”
BackgroundHsu, A. J., Hanisch, B. R., Fisher, B. T., & Huppler, A. R. (2024) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piad115 · Cited by 15 · see citing works
Candida auris : host interactions, antifungal drug resistance, and diagnostics
Chowdhary, A., Lionakis, M. S., & Chauhan, N. (2025) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00187-22 · Cited by 13 · see citing works
Siddiqui, T., Kumar, K. A., Iqbal, A., Doultani, P. R., Ashraf, T., Eqbal, F., & Siddiqui, S. I. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20495 · Cited by 11 · see citing works
“…(hazard ratio [95 % confidence interval], 0.11 [0.06 to 0.21] for CL-011 and 0.08 [0.04 to 0.17] for CL-012; P < 0.001) having strong effectiveness against fluconazole-resistant C. albicans and C. glabrata species, in avoiding the recurrence in VVC participants with a history of RVVC [13].”
BackgroundInfluentialCurrent Antifungals and the Developing Pipeline
Johnson, M. D., & Moore, W. J. (2025) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2025.01.001 · Cited by 11 · see citing works
An update on newer antifungals
Akinosoglou, K., Papageorgiou, D., Gogos, C. A., & Dimοpoulos, G. (2025) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2025.2461566 · Cited by 10 · see citing works
“…exhibited similar incidence of treatment-emergent adverse events (TEAEs) with the comparator’s groups, with mainly mild to moderate reported adverse events including nausea, headache, urinary tract infection and bacterial vulvovaginitis (Table 4 shows most commonly reported adverse events) [14,16].”
Powell, A. M., Sarria, I., & Goje, O. (2023) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2023.02.005 · Cited by 10 · see citing works
Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis
Vanreppelen, G., Nysten, J. V., Baldewijns, S., Sillen, M., Donders, G. G. G., & Dijck, P. V. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.10.004 · Cited by 9 · see citing works
Self-citationHost defense mechanisms against Candida auris
Pechacek, J., & Lionakis, M. S. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2264500 · Cited by 5 · see citing works
Gardella, B., Dominoni, M., Cassani, C., Pasquali, M. F., & Spinillo, A. (2025) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2025.03.031 · Cited by 7 · see citing works
Quindós, G., Marcos‐Arias, C., Miranda-Cadena, K., Sevillano, E., Jauregizar, N., Schneider, J., & Eraso, E. (2025) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2025.2516554 · Cited by 5 · see citing works
“In most clinical trials, up to 95% of patients had no recurrences during long-term follow-up, compared to 60% in the fluconazole-treated group [87–92].”
Therapeutic Tools for Vulvovaginal Candidiasis: Current and Emerging Antifungal Agents
Quindós, G., De-la-Pinta, I., Marcos‐Arias, C., Jauregizar, N., Sevillano, E., Madariaga, L., & Eraso, E. (2026) · Journal of Fungi · doi:10.3390/jof12020152 · Cited by 4 · see citing works
“In vitro, oteseconazole is approximately 40-fold more potent than fluconazole against most Candida species [12,51,79,80].”
InfluentialTO MARKET, TO MARKET–2022: SMALL MOLECULES
Araujo, E., Bell, I. M., Burckle, A. J., Koester, D. C., Manning, J. R., Castanedo, G. M., Zeng, M., Dhar, T. G. M., Holmberg‐Douglas, N., Welin, E. R., et al. (2023) · Medicinal chemistry reviews · doi:10.1021/mc-2023-vol58.ch24 · Cited by 4 · see citing works
Sustained Efficacy of Oteseconazole in Women with Recurrent Vulvovaginal Candidiasis
Lederman, S. N., Sobel, R., Sobel, J. D., Curelop, S., & Brand, S. R. (2025) · Journal of Women s Health · doi:10.1177/15409996251394811 · Cited by 3 · see citing works
Self-citationUpdate on Therapies and Treatments in Women’s Health
Prifti, C. A., Casas, R. S., Merriam, S. B., Yecies, E. B., & Walsh, J. M. E. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2024.03.007 · Cited by 3 · see citing works
Current Progression in Nanomedicine for the Treatment of Candida albicans Infections
Chopra, S., Kumar, A., Pandit, V., Kumar, P., Ankalgi, A. D., & Ashawat, M. S. (2025) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-025-00284-7 · Cited by 2 · see citing works
“Furthermore, riboflavin is an outstanding pho - tosensitizer, making it highly effective in Light-activated antimicrobial therapy, generating oxidative radicals to eliminate harmful microbes [ 64 ].”
Angelini, J., Ferin, S., Martini, L., Flammini, S., Tascini, C., & Giuliano, S. (2026) · Clinical Microbiology Reviews · doi:10.1128/cmr.00228-25 · Cited by 2 · see citing works
Das, S. K., & Konwar, B. K. (2025) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-025-10574-7 · Cited by 1 · see citing works
The Treatment Challenge of Vulvovaginal Candida glabrata: A Case Report
Knoeckel, S. (2025) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2025.105418 · Cited by 1 · see citing works
Lalwani, A., Singh, S. D., Parua, S., Ahuja, D., Adhikary, K., Maiti, R., Bhattacharya, K., Banerjee, S. K., & Syamal, A. K. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128388596251001075837 · Cited by 1 · see citing works
Scott, T. L., Quezado, M., & Williamson, P. R. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2628049 · Cited by 1 · see citing works
“Other agents include VT-1161 (otesecona-zole), a long-acting fungicidal azole effective in recurrent vul-vovaginal candidiasis [64] is currently undergoing a phase two trial comparing single dose IV L-AMB + oteseconazole to the world health standard of care induction/consolidation regimen using…”
Novel Antifungals for the Treatment of Vulvovaginal Candidiasis: Where Are We?
Gamal, A., authorship, T. A. H. C. E. T. T. W. A. S. F., Kadry, A., authorship, T. A. H. C. E. T. T. W. A. S. F., Elshaer, M. Y. S., & Ghannoum, M. A. (2022) · touchREVIEWS in Infectious Diseases · doi:10.17925/id.2022.1.1.16 · Cited by 1 · see citing works
Self-citationOteseconazole in recurrent vulvovaginal candidiasis: a profile of its use
Fung, S. S.-P., & Shirley, M. (2023) · Drugs & Therapy Perspectives · doi:10.1007/s40267-023-01008-x · Cited by 1 · see citing works
“Oteseconazole, as a maintenance phase treatment, reduces the recurrence of VVC following induction phase treatment with fluconazole [17].”
InfluentialCLINICAL MANAGEMENT OF RECURRENT CANDIDIASIS: WHAT DOES THE EVIDENCE SAY?
Bezerra, P. V. S., Neto, G. C. D. A. M., pimentel, C. F., Betmann-Azevêdo, K., Lins, J. R. D. V., Silva, B. O. G. E., Amorim, P. H. B. D. M., Correia, M. M. G., Patriota, M. C. A. M., Santos, M. P. D. M., et al. (2024) · International Journal of Health Science · doi:10.22533/at.ed.15944724290510
Antifungal Agents and Therapeutic Approaches in the Treatment of Invasive Fungal Infections
Choudhary, P., Punia, A., Kumari, S., & Chhillar, A. K. (2025) · Current Bioactive Compounds · doi:10.2174/0115734072368372250203055808
Raman, C. V., Rajamohanan, R. R., & Udayashankar, C. (2025) · Indian Journal of Sexually Transmitted Diseases and AIDS · doi:10.4103/ijstd.ijstd_71_25
“[3,4] It is available as a 150 mg capsule.”
Modern trends in the development of antifungal agents
Avtonomova, A. V., Валерьевна, К. О., Zagainova, A. V., & Makarov, V. V. (2025) · Экология человека · doi:10.17816/humeco695458
Avtonomova, A. V., Валерьевна, К. О., Lysenkova, L. N., & Krasnopolskaya, T. S. (2025) · Antibiot Khimioter = Antibiotics and Chemotherapy · doi:10.37489/0235-2990-2025-70-9-10-62-76
Chen, T., Wu, Y., Chen, Y., Li, Y. P., Zhao, H., Wu, L., Gao, H., Jiang, T., Wang, X., Chen, M., et al. (2026) · Interdisciplinary medicine · doi:10.1002/inmd.70128
Antifungal interventions and clinical outcomes: A review
Simran, S., Gaba, P., Sharma, N., & Singh, J. (2026) · Scripta Medica · doi:10.5937/scriptamed57-58699
Kumondai, M., Yagi, A., Watanabe, M., Lyu, Y., Segawa, R., Sato, M., Tadakuma, R., Inoue, K., Watanabe, H., Takeda, M., et al. (2026) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2026.100343
Gerwen, O. T. V., KISSINGER, P. J., & Muzny, C. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45863-7.00042-1
de Farias, E. H., Pereira, A. G. A., da Silva, A. M. P., Cabeça, L. S., Vieira, L. L. P., Magalhães, P. L. M., Júnior, J. D. S. V., & Eleutério, J. (2026) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.61622/rbgo/2026rbgo32
“(18) Oteseconazole has a potent activity against a broad spectrum of Candida species, including fluconazole-resistant strains such as C. glabrata , as reflected by its substantially lower minimum inhibitory concentrations (MICs) compared to fluconazole.”
Emerging antifungal agents in human medicine: Mechanisms, clinical progress, and future perspectives
Al‐Zoubi, R. M., Farhan, A., Hanbali, B., Al-Zoubi, S. R., Al-Zoubi, Y. R., Shkoor, M., Alkharraz, L. M., Agouni, A., & Al-Jabiry, A. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119194
Systemic Antifungal Safety During Pregnancy: A Narrative Review
Alshehail, B. M. (2026) · Journal of Applied Pharmaceutical Science · doi:10.1177/22313354261453150
“33 A total of 13 pregnancies were reviewed (eight participants taking oteseconazole [six healthy births, one unknown outcome, and one elective termination]; five taking placebo [three healthy births, one unknown outcome, and one elective termination]).”
Yan, Z., Cui, Y., Li, Y., Xiao, X., Liao, M., Liu, X., Zhou, W., Kuang, L., & Jiang, Y. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1944046
Samadi, Y., Ajmal, Z., Ishaque, R., Mohammed, A. A., Irshad, K., Ahmer, M., Nakrash, R. M., Alghamdi, B. K., Alsaleh, A. M., Khaled, K. R. A., et al. (2026) · Journal of International Medical Research · doi:10.1177/03000605261476919
Management of Recurrent Vaginitis
Yazdy, G. M., Powell, A. M., & Tuddenham, S. (2026) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2026.08.010
The Antifungal Pipeline: New and Future Antifungals
Hendrix, C., Blum, S., Zuniga-Moya, J. C., Spec, A., & Rauseo, A. M. (2026) · Current Clinical Microbiology Reports · doi:10.1007/s40588-026-00280-5
“Up to 96% of women receiving oteseconazole remained infection free compared to 61% receiving placebo [57].”
- Authors
- Sobel, J. D., Donders, G., Degenhardt, T., Person, K., Curelop, S., Ghannoum, M., & Brand, S. R.
- Affiliations
- Wayne State University (US)
- Antwerp University Hospital (BE)
- Mycovia Pharmaceuticals (United States) (US)
- Case Western Reserve University (US)
- ORCID
- Venue
- NEJM Evidence
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-26
- Volume
- 1
- Issue
- 8
- Pages
- EVIDoa2100055-EVIDoa2100055
- ISSN
- 2766-5526 (ISSN-L)
- OpenAlex
- W4288009948
- Semantic Scholar
- 5e1ed9175a0a2e81fc1fbbdaf2a3d5373ab96acc
- Cited by
- 55
- References
- 25
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 6 · 2023: 12 · 2022: 5
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- NEJM Evidence (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
- Health Sciences › Medicine › Epidemiology › Urinary Tract Infections Management
- Keywords
- oteseconazole, recurrent vulvovaginal candidiasis, CYP51 inhibitors, antifungal therapy, time to recurrence, treatment safety, patient-reported outcomes, women's health, adverse events, treatment discontinuation, quality of life
- MeSH terms
- Adolescent, Adult, Antifungal Agents, Candidiasis, Vulvovaginal, Double-Blind Method, Female, Humans, Middle Aged, Recurrence, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
